Return to Publications
January 2017
RWJBarnabas HealthRutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including clinical trials and novel therapeutics such as precision medicine and immunotherapy.

Pinpointing Recurrent Genomic Alterations in Breast Cancer

A genomic analysis study by Rutgers Cancer Institute of New Jersey investigators and others has identified recurrent genomic alterations in a subset of breast cancer that are typically associated with a form of thyroid cancer and an intestinal birth defect. Associate Director for Translational Science and Omar Boraie Chair in Genomic Science Shridar Ganesan, MD, PhD, and breast medical oncologist Kim M. Hirshfield, MD, PhD, who are both faculty members at Rutgers Robert Wood Johnson Medical School, were involved in the work that was presented at the recent San Antonio Breast Cancer Symposium.

Shawna Hudson, PhD

Examining the Role of Primary Care Providers in Cancer Survivorship

For more than a decade, there has been a focus on involving primary care providers in the follow-up care of cancer survivors. A new study by Rutgers University and Harvard Medical School finds that despite a number of proposed care models, there is limited information on the role that primary care providers play in this care. Rutgers Cancer Institute research member Shawna V. Hudson, PhD, associate professor and research division chief in the Department of Family Medicine and Community Health at Rutgers Robert Wood Johnson Medical School, is the senior author of the work that appears in The Lancet Oncology.

St. Baldrick's Foundation

A Boost for Childhood Cancer Research at Rutgers Cancer Institute

Childhood cancer patients rely on clinical trials to find better, safer cures that can prevent lifelong damage as a result of radiation and chemotherapy. Rutgers Cancer Institute of New Jersey has been awarded an infrastructure grant from the St. Baldrick's Foundation to expand access to clinical trials. Funding from St. Baldrick's totaling $50,000 will ensure that additional adolescent and young adult patients can be treated by clinical trials with the most innovative drugs and therapies available at Rutgers Cancer Institute.

Janice Mehnert, MD

A Closer Look at Immunotherapy in Cancer

Ever since the first vaccines were created in the 1700s, doctors have been finding ways to force the body's own immune system to fight disease. One of the more difficult targets for immunotherapy has been cancer, but recent advances in the field have turned immuno-oncology into one of the most promising frontiers in medicine. Janice M. Mehnert, MD, director of the Phase I/Investigational Therapeutics Program at Rutgers Cancer Institute of New Jersey and associate professor of medicine at Rutgers Robert Wood Johnson Medical School, shares some insight in this recent article.